Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q1 2024 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2024-05-14 · accession 0000902664-24-003553

$135.3M
Reported value
11
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$43.2M31.9%7,000,000CommonSOLE
00534A102IVVDINVIVYD INC$41.1M30.3%9,248,250CommonSOLE
35168W103GUTSFRACTYL HEALTH INC$13.7M10.1%1,856,117CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$10.4M7.68%385,680CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$6.5M4.78%299,400CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$5.4M4.02%110,400CommonSOLE
231269309CRISCURIS INC$4.6M3.39%421,951CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$3.7M2.77%121,200CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$2.5M1.82%161,600CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$2.3M1.73%1,019,498CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$1.9M1.42%67,400CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.